Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.

Authors:
Dr Fernando Torres Andón, PhD
Dr Fernando Torres Andón, PhD
University of Santiago de Compostela
AECC Researcher in Nanomedicine for Cancer Immunotherapy
Nanomedicine - Cancer Immunotherapy - Nanotoxicology - Cell Death
Santiago de Compostela, A Coruña | Spain
Maria Jose Alonso
Maria Jose Alonso
University of Santiago de Compostela
Spain

J Drug Target 2015 ;23(7-8):656-71

b Center for Research in Molecular Medicine & Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela , Spain .

The search for pharmacological strategies to reach and impact on immunosuppressive cells is, currently, one of the most exciting areas in cancer immunology and clinical oncology. In this context, it is increasingly accepted that the success of these therapies will largely depend on the availability of appropriate drug delivery strategies. Considering the critical role that nanotechnology plays in the development of these novel therapies, the main goal of this article is to provide an overview of the potential of nanomedicines targeted to immunosuppressive cells for the treatment of cancer. We present, first, a brief description of classical cancer immunotherapies based on therapeutic vaccination and monoclonal antibodies, with a special focus on the use of nanotechnologies and the targeting of immunological checkpoints. Second, we provide a thoughtful analysis of the possibilities to target the immunosuppressive cells, namely tumour-associated macrophages, myeloid-derived suppressor cells, tumour-associated neutrophils and regulatory T cells, at the tissue level (i.e. tumour, spleen, blood, lymph) and, also, at the cellular level. Finally, we wrap the article with a disclosure of strategies used to impair the generation, kill or re-educate these immunosuppressive cells, thus providing an up-to-date picture of the choices available for therapeutic intervention.

Download full-text PDF

Source
http://dx.doi.org/10.3109/1061186X.2015.1073295DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2016
5 Reads
1 Citation

Publication Analysis

Top Keywords

immunosuppressive cells
20
cells tumour-associated
8
cells
7
immunosuppressive
5
special focus
4
focus nanotechnologies
4
antibodies special
4
therapeutic vaccination
4
vaccination monoclonal
4
monoclonal antibodies
4
nanotechnologies targeting
4
based therapeutic
4
thoughtful analysis
4
analysis possibilities
4
provide thoughtful
4
second provide
4
immunological checkpoints
4
checkpoints second
4
targeting immunological
4
classical cancer
4

References

(Supplied by CrossRef)
Article in Swiss Med Wkly
Fadeel B et al.
Swiss Med Wkly 2012

Similar Publications